KR20230136913A - Cd28 및 pd-l1을 표적화하기 위한 다중특이적 항체 및 그의 사용 방법 - Google Patents

Cd28 및 pd-l1을 표적화하기 위한 다중특이적 항체 및 그의 사용 방법 Download PDF

Info

Publication number
KR20230136913A
KR20230136913A KR1020237017803A KR20237017803A KR20230136913A KR 20230136913 A KR20230136913 A KR 20230136913A KR 1020237017803 A KR1020237017803 A KR 1020237017803A KR 20237017803 A KR20237017803 A KR 20237017803A KR 20230136913 A KR20230136913 A KR 20230136913A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
light chain
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237017803A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 캠벨
토마스 알 디라이몬도
Original Assignee
재눅스 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재눅스 테라퓨틱스 인크. filed Critical 재눅스 테라퓨틱스 인크.
Publication of KR20230136913A publication Critical patent/KR20230136913A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237017803A 2020-10-30 2021-10-29 Cd28 및 pd-l1을 표적화하기 위한 다중특이적 항체 및 그의 사용 방법 Pending KR20230136913A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202063107942P 2020-10-30 2020-10-30
US63/107,942 2020-10-30
US202063123329P 2020-12-09 2020-12-09
US202063123327P 2020-12-09 2020-12-09
US63/123,327 2020-12-09
US63/123,329 2020-12-09
US202163141268P 2021-01-25 2021-01-25
US63/141,268 2021-01-25
US202163187699P 2021-05-12 2021-05-12
US202163187719P 2021-05-12 2021-05-12
US202163187690P 2021-05-12 2021-05-12
US63/187,719 2021-05-12
US63/187,690 2021-05-12
US63/187,699 2021-05-12
US202163189843P 2021-05-18 2021-05-18
US63/189,843 2021-05-18
PCT/US2021/057384 WO2022094299A2 (en) 2020-10-30 2021-10-29 Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20230136913A true KR20230136913A (ko) 2023-09-27

Family

ID=81384468

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017803A Pending KR20230136913A (ko) 2020-10-30 2021-10-29 Cd28 및 pd-l1을 표적화하기 위한 다중특이적 항체 및 그의 사용 방법

Country Status (8)

Country Link
US (1) US20230406937A1 (https=)
EP (1) EP4237013A4 (https=)
JP (1) JP2023548443A (https=)
KR (1) KR20230136913A (https=)
AU (1) AU2021369835A1 (https=)
CA (1) CA3196726A1 (https=)
MX (1) MX2023005081A (https=)
WO (1) WO2022094299A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP2024518539A (ja) 2020-04-04 2024-05-01 ジャナックス セラピューティクス，インク． 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法
EP4259177A4 (en) * 2020-12-08 2024-11-06 Janux Therapeutics, Inc. Peptide compositions and methods for anti-cd3 binding domains
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CA3267921A1 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. MULTISPECIFIC PROTEINS AND ASSOCIATED PROCESSES
WO2024102723A2 (en) * 2022-11-10 2024-05-16 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
EP4615879A2 (en) * 2022-11-11 2025-09-17 Janux Therapeutics, Inc. Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
CN121532427A (zh) * 2023-05-18 2026-02-13 首尔大学校产学协力团 抗cd40l/抗cd28双特异性抗体及其用途
WO2025026356A1 (zh) * 2023-07-31 2025-02-06 百奥泰生物制药股份有限公司 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用
WO2025090973A2 (en) * 2023-10-27 2025-05-01 Xencor, Inc. Anti-trop2 x anti-pdl1 x anti-cd28 antibodies
TW202528349A (zh) * 2023-11-03 2025-07-16 美商詹努克斯治療有限公司 用於靶向psma及cd28之抗體及其用途
TW202535942A (zh) * 2023-11-03 2025-09-16 美商詹努克斯治療有限公司 用於靶向cd28之抗體及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520650A (ja) * 2015-05-21 2018-08-02 アリゲーター・バイオサイエンス・アーベー 新規のポリペプチド
EP3307778A1 (en) * 2015-06-12 2018-04-18 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
US20190233534A1 (en) * 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
EP3645050A4 (en) * 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
US20220017617A1 (en) * 2018-07-09 2022-01-20 Shanghai Epimab Biotherapeutics Co., Ltd. Efficiently expressed egfr and pd-l1 bispecific binding proteins
JP2022513495A (ja) * 2018-12-21 2022-02-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
TWI861039B (zh) * 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
WO2020198009A1 (en) * 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. EGFR x CD28 MULTISPECIFIC ANTIBODIES

Also Published As

Publication number Publication date
EP4237013A2 (en) 2023-09-06
JP2023548443A (ja) 2023-11-16
AU2021369835A9 (en) 2024-07-11
US20230406937A1 (en) 2023-12-21
CA3196726A1 (en) 2022-05-05
WO2022094299A2 (en) 2022-05-05
AU2021369835A1 (en) 2023-06-01
MX2023005081A (es) 2023-06-15
WO2022094299A3 (en) 2022-09-29
EP4237013A4 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
KR20230136913A (ko) Cd28 및 pd-l1을 표적화하기 위한 다중특이적 항체 및 그의 사용 방법
JP7681681B2 (ja) 切断可能リンカー組成物および方法
TWI900703B (zh) 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法
US12161724B2 (en) Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
JP2023552462A (ja) 半減期延長組成物および方法
EP4259202A1 (en) Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
WO2022240865A1 (en) Antibodies targeting egfr and cd3 and uses thereof
US20230357447A1 (en) Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
US20250154278A1 (en) Optimized antibodies targeting trop2 and uses thereof
US20240043565A1 (en) Antibodies targeting psma and cd3 and uses thereof
CN120435318A (zh) 靶向egfr和cd3的抗体及其用途
CN117098562A (zh) 用于靶向cd28和pd-l1的多特异性抗体及其使用方法
CN116997573A (zh) 靶向psma和cd3的抗体及其用途
HK40109153A (zh) 涉及靶向egfr和效应细胞抗原的肿瘤活化抗体的组合物和方法
CN117042801A (zh) 涉及靶向trop2和效应细胞抗原的肿瘤活化抗体的组合物和方法
CN117042792A (zh) 涉及靶向psma和效应细胞抗原的肿瘤活化抗体的组合物和方法
HK40101255A (zh) 涉及靶向psma和效应细胞抗原的肿瘤活化抗体的组合物和方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241028

Comment text: Request for Examination of Application